ELVN Stock Summary and Trading Ideas (Enliven Therapeutics | NASDAQ:ELVN)

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

Enliven Therapeutics trades on the NASDAQ stock market under the symbol ELVN.

As of February 4, 2026, ELVN stock price climbed to $27.82 with 886,572 million shares trading.

ELVN has a beta of 0.92, meaning it tends to be less sensitive to market movements. ELVN has a correlation of 0.04 to the broad based SPY ETF.

ELVN has a market cap of $1.65 billion. This is considered a Small Cap stock.

The top ETF exchange traded funds that ELVN belongs to (by Net Assets): IWM, VTI, IWO, IBB, VXF.

ELVN has outperformed the market in the last year with a price return of +27.0% while the SPY ETF gained +16.0%. ELVN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +39.1% and +2.8%, respectively, while the SPY returned +0.7% and +1.3%, respectively.

ELVN support price is $26.20 and resistance is $29.00 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ELVN shares will trade within this expected range on the day.